Boehringer, Hospira Products Adulterated, FDA Warns

Law360, Los Angeles (May 21, 2013, 4:34 PM EDT) -- The U.S. Food and Drug Administration on Tuesday released warning letters it sent to generic-drug maker Hospira Inc. and German pharmaceutical company Boehringer-Ingelheim Pharma GmbH & Co. KG warning the companies of several products that are considered adulterated due to inadequate manufacturing processes.

The letters, sent to Boehringer and Hospira on May 6 and May 9, respectively, outline various violations of current good manufacturing practice stemming from the inspections of a Boehringer manufacturing facility in Germany and Hospira’s firm in Illinois.

The FDA says a November...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.